Is Spravato® FDA-approved for OCD?

No. It is FDA-approved for treatment-resistant depression (TRD) and for depressive symptoms in MDD with acute suicidal ideation or behavior. OCD use is off-label and considered case by case after standard therapies are optimized.

How fast might OCD symptoms change?

Anti-obsessional effects can appear within days in some ketamine data, but OCD improvements with intranasal esketamine are often more gradual and varied, commonly emerging over weeks 8 to 12 in responders. Depression, if present, may improve sooner.

Do I still need ERP therapy?

Yes. We strongly recommend pairing esketamine with ERP to reinforce new learning during periods of increased neuroplasticity.

What are common side effects?

Transient dizziness, brief dissociation, nausea, and temporary blood-pressure increases. We monitor you throughout the visit, and you should not drive until the next day.

Can esketamine be combined with TMS?

Yes. For TRD plus OCD, a combined or sequenced approach (esketamine, TMS and ERP) may optimize speed and durability. We will individualize the plan.

Spravato® for OCD | Florida TMS Clinic

Off-label notice

Spravato® (esketamine) is FDA-approved for treatment-resistant depression and for MDD with acute suicidal ideation or behavior, not for OCD. Any OCD use is off-label and considered only after standard therapies are optimized.

Why consider esketamine for OCD?

Many people with obsessive-compulsive disorder (OCD) respond to high-dose SSRIs, clomipramine, and exposure-and-response prevention (ERP) therapy. But when intrusive thoughts and compulsions persist despite best-practice care, clinicians may consider glutamatergic strategies. Spravato® (esketamine) targets the NMDA receptor within the glutamate system, a pathway implicated in obsessive thinking, cognitive rigidity, and anxiety, offering a mechanistically distinct option from serotonin-based medications.

What the evidence shows (current, evolving)

Intranasal esketamine case series (adult treatment-resistant OCD with MDD): over about 12 weeks, patients receiving 56 to 84 mg intranasal esketamine showed meaningful average reductions in OCD severity (Y-BOCS) and robust antidepressant effects; a subset met OCD response criteria. Effects on depression tended to appear earlier than OCD gains.
Retrospective augmentation data: in treatment-resistant OCD cohorts, off-label esketamine added to ongoing therapy was associated with symptom improvements for some patients, supporting feasibility and safety under clinic supervision.
Mechanistic and ketamine literature: randomized crossover data with IV ketamine demonstrate rapid anti-obsessional effects, consistent with glutamatergic modulation of cortico-striato-thalamo-cortical circuits. Benefits may be amplified when paired with ERP.

Evidence is preliminary; larger, controlled trials are needed. We individualize decisions and track outcomes with measurement-based care.

Key takeaways

If you are in immediate crisis, call 988 (Suicide & Crisis Lifeline) or 911.

OCD response is possible but variable; depression often improves faster.
Best outcomes are likely when esketamine is paired with ERP-based CBT.
The safety profile is generally transient: brief dissociation, dizziness, nausea, temporary blood pressure increases, all monitored on site.

How treatment works at Florida TMS Clinic

We coordinate with your therapist to schedule ERP during the acute phase. Leveraging esketamine-related neuroplasticity may help patients resist compulsions and reinforce new learning.

Eligibility and planning: confirm diagnosis, prior trials (SSRIs/SRIs, clomipramine, antipsychotic augmentation), ERP engagement, and medical suitability.
Program: induction typically 2 visits per week for about 4 weeks, then taper to weekly or biweekly as appropriate. Dosing is individualized within the 56 to 84 mg range under REMS supervision.
Visit length: about 2 hours including administration, recovery, and monitoring (vitals, comfort).
Aftercare: no driving until the next day; arrange a safe ride.
Measurement-based care: we track Y-BOCS for OCD and depression scales to guide continuation.

Esketamine vs. TMS for OCD: which is right for me?

Both Transcranial Magnetic Stimulation (TMS) and Spravato® (esketamine) are considered for complex OCD cases, especially when depression coexists. Many patients benefit from a sequenced or combined approach.

Speed: esketamine may act in days; TMS often builds over 2 to 6+ weeks.
Mechanism: esketamine is glutamatergic modulation; TMS is circuit-specific neuromodulation.
Session experience: esketamine requires monitored visits of about 2 hours; TMS has no observation period.
Driving: after esketamine, no driving until the next day; after TMS, driving is allowed.
Combination: for TRD plus OCD, pairing strategies (esketamine, TMS and ERP) may optimize speed and durability.
Urgent relief needed? Begin with esketamine, then add or transition to TMS for durability.
Prefer non-medication first? Start with TMS; consider esketamine if response is incomplete.
High-severity TRD plus OCD? A combined strategy with coordinated ERP.

Who is a good candidate?

We are a REMS-certified center. Common effects are transient and resolve during on-site observation. We review risks, benefits, and alternatives and proceed only with shared decision-making.

Adults with treatment-resistant OCD after optimized SSRI/SRI, with or without clomipramine, and augmentation trials.
Active engagement (or readiness) for ERP-based CBT.
Co-occurring treatment-resistant depression (where Spravato® is on-label) is common and may strengthen the case for a trial.
Medically appropriate for supervised intranasal therapy and follow-up.

Esketamine in Wesley Chapel and Tampa

Florida TMS Clinic, Tampa: serving Tampa, South Tampa, Downtown, and Westshore. Same-week evaluations often available.

Florida TMS Clinic, Wesley Chapel: serving Wesley Chapel, New Tampa, Lutz, Land O' Lakes, and North Tampa communities.

Take the first step

If best-practice OCD care hasn't been enough, our team can evaluate whether an off-label esketamine trial makes sense, often in combination with ERP and, when appropriate, TMS.